xiyouji qingzhi capsules
DESCRIPTION
FDA warns the consumers not to use Xiyouji qingzhi capsules, on 10th june 2013.TRANSCRIPT
FDA warns against “XIYOUJI QINGZHI
CAPSULE ”
P.Naina Mohamed
Pharmacologist
IntroductionThe Food and Drug Administration (FDA)
is advising consumers not to purchase or use “XIYOUJI QINGZHI CAPSULE,” a product promoted and sold for weight loss on various websites, including www.jadera.net, on 10th June 2013.
FDA laboratory analysis confirmed that “XIYOUJI QINGZHI CAPSULE” contains sibutramine. Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons.
Possible Mechanism of action
XIYOUJI QINGZHI CAPSULE
Contains Sibutramine
Affects Ventromedial & lateral hypothalamic regions of CNS
Blockade of Serotonin (5-HT), Noradrenaline and Dopamine reuptake
Increase the neurotransmission of Serotonin (5-HT), Noradrenaline and Dopamine
Rise of Satiety (Absence of hunger after eating) and reduction of hunger
Loss of Appetite
Risks of XIYOUJI QINGZHI CAPSULE
Undeclared ingredient (Sibutramine)
Inhibit the reuptake of mono amines (Serotonin, Noradrenaline and Dopamine)
Increased neurotransmission of mono amines
Elevated blood pressure and Heart
Increased risk of Nonfatal myocardial infarction and nonfatal stroke in patients with preexisting cardiovascular diseases
Serious Drug Interactions
Undeclared ingredient (Sibutramine)
Interacts with Mono amine oxidase inhibitors (MAOIs)
Inhibition of metabolism of monoamines
Increased plasma level of monoamines
Serious, sometimes fatal, reactions (“serotonin syndrome”)
Excitement, hypomania, restlessness, loss of consciousness, confusion, disorientation, anxiety, agitation, motor weakness,
myoclonus, tremor, hemiballismus, hyperreflexia, ataxia, dysarthria, incoordination, hyperthermia, shivering, pupillary
dilation, diaphoresis, emesis, and tachycardia.
Other Drug Interactions
Undeclared ingredient (Sibutramine)
Interacts with Decongestants (Ephedrine or Pseudoephedrine)
May raise blood pressure or heart rate
Other Drug Interactions
Undeclared ingredient (Sibutramine)
Interacts with CYP3A4 enzyme inhibitors like Ketoconazole, Erythromycin, etc.
Increase the plasma level of Sibutramine
Toxicity of Sibutramine
FDA WarningsFDA warns the Consumers should stop using this product
immediately and throw it away. FDA advises the Consumers who have experienced any
negative side effects should consult a health care professional as soon as possible.
FDA announces to the public of a growing trend of dietary supplements or conventional foods with hidden drugs and chemicals. These products are typically promoted for sexual enhancement, weight loss, and body building, and are often represented as being “all natural.”
FDA claims that they are unable to test and identify all products marketed as dietary supplements on the market that have potentially harmful hidden ingredients.
FDA advises the Consumers to exercise caution before purchasing any product in the above categories.
FDA Warnings FDA has requested market withdrawal after reviewing data from
the Sibutramine Cardiovascular Outcomes Trial (SCOUT). SCOUT is part of a postmarket requirement to look at cardiovascular safety of sibutramine after the European approval of the drug. The trial demonstrated a 16 percent increase in the risk of serious heart events, including non-fatal heart attack, non-fatal stroke, the need to be resuscitated once the heart stopped, and death, in a group of patients given sibutramine compared with another given placebo. There was a small difference in weight loss between the placebo group and the group that received sibutramine.
RECOMMENDATION: Physicians are advised to stop prescribing Meridia to their patients, and patients should stop taking this medication. Patients should talk to their health care provider about alternative weight loss and weight loss maintenance programs.
http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm228830.htm
References http://www.fda.gov/Drugs/
ResourcesForYou/Consumers/BuyingUsingMedicineSafely/MedicationHealthFraud/ucm355797.htm
CURRENT Diagnosis & Treatment: Gastroenterology, Hepatology, & Endoscopy, 2eNorton J. Greenberger, Richard S. Blumberg, Robert Burakoff
Clinician's Pocket Reference, 11eLeonard G. Gomella, Steven A. Haist
Harrison's Online Featuring the complete contents of Harrison's Principles ofInternal Medicine, 18e
Basic & Clinical Pharmacology, 12e Bertram G. Katzung, Susan B. Masters, Anthony J. Trevor
References http://www.fda.gov/safety/medwatch/safetyi
nformation/safetyalertsforhumanmedicalproducts/ucm228830.htm
http://www.tga.gov.au/safety/alerts-medicine-sibutramine-101008.htm
http://www.medsafe.govt.nz/hot/media/2010/SibutramineOct2010.asp
http://www.bmj.com/content/340/bmj.c824